Indium In-111 chloride API Manufacturers

General Description:

Indium In-111 chloride, identified by CAS number 50800-85-6, is a notable compound with significant therapeutic applications. Indium In-111 Chloride is a diagnostic radiopharmaceutical agent intended for radiolabeling OncoScint (satumomab pendetide) or ProstaScint (capromab pendetide) used for _in vivo_ diagnostic imaging procedures and for radiolabeling Zevalin (ibritumomab tiuxetan) in preparations used for radioimmunotherapy procedures. It is supplied as a sterile, pyrogen-free solution of Indium ("'In) Chloride in O.04M HCI.

Indications:

This drug is primarily indicated for: Indium In-111 Chloride is indicated for radio labeling of monoclonal antibodies in preparations used for in vivo diagnostic imaging procedures. Indiclor is also indicated for radiolabeling Zevalin in preparations used for radio immunotherapy procedure. Its use in specific medical scenarios underscores its importance in the therapeutic landscape.

Metabolism:

Indium In-111 chloride undergoes metabolic processing primarily in: Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Its metabolism is related to the final product and not specific to Indium In-111 Chloride alone. This metabolic pathway ensures efficient processing of the drug, helping to minimize potential toxicity and side effects.

Absorption:

The absorption characteristics of Indium In-111 chloride are crucial for its therapeutic efficacy: Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Its absoption is related to the final product and not specific to Indium In-111 Chloride alone. The drug's ability to rapidly penetrate into cells ensures quick onset of action.

Half-life:

The half-life of Indium In-111 chloride is an important consideration for its dosing schedule: 2.8 days. This determines the duration of action and helps in formulating effective dosing regimens.

Protein Binding:

Indium In-111 chloride exhibits a strong affinity for binding with plasma proteins: Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Its protein binding is related to the final product and not specific to Indium In-111 Chloride alone. This property plays a key role in the drug's pharmacokinetics and distribution within the body.

Route of Elimination:

The elimination of Indium In-111 chloride from the body primarily occurs through: Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Itsroute of elimination is related to the final product and not specific to Indium In-111 Chloride alone. Understanding this pathway is essential for assessing potential drug accumulation and toxicity risks.

Volume of Distribution:

Indium In-111 chloride is distributed throughout the body with a volume of distribution of: Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Its volume of distribution is related to the final product and not specific to Indium In-111 Chloride alone. This metric indicates how extensively the drug permeates into body tissues.

Clearance:

The clearance rate of Indium In-111 chloride is a critical factor in determining its safe and effective dosage: Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Its clearance is related to the final product and not specific to Indium In-111 Chloride alone. It reflects the efficiency with which the drug is removed from the systemic circulation.

Pharmacodynamics:

Indium In-111 chloride exerts its therapeutic effects through: Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Its pharmacodynamics is related to the final product and not specific to Indium In-111 Chloride alone. The drug's ability to modulate various physiological processes underscores its efficacy in treating specific conditions.

Mechanism of Action:

Indium In-111 chloride functions by: Indium In-111 Chloride is a radioactive tracer for labeling monoclonal antibodies in certain preparations such as OncoScint, ProstaScint and Zevalin. Its mechanism of action is related to the final product and not specific to Indium In-111 Chloride alone. This mechanism highlights the drug's role in inhibiting or promoting specific biological pathways, contributing to its therapeutic effects.

Toxicity:

Classification:

Indium In-111 chloride belongs to the class of inorganic compounds known as post-transition metal chlorides. These are inorganic compounds in which the largest halogen atom is Chlorine, and the heaviest metal atom is a post-transition metal, classified under the direct parent group Post-transition metal chlorides. This compound is a part of the Inorganic compounds, falling under the Mixed metal/non-metal compounds superclass, and categorized within the Post-transition metal salts class, specifically within the Post-transition metal chlorides subclass.

Categories:

Indium In-111 chloride is categorized under the following therapeutic classes: Radioactive Diagnostic Agent, Radiopharmaceutical Activity. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.